151 related articles for article (PubMed ID: 36353989)
21. Low density lipoprotein receptor-related protein 1 dependent endosomal trapping and recycling of apolipoprotein E.
Laatsch A; Panteli M; Sornsakrin M; Hoffzimmer B; Grewal T; Heeren J
PLoS One; 2012; 7(1):e29385. PubMed ID: 22238606
[TBL] [Abstract][Full Text] [Related]
22. Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.
Romagnuolo R; Scipione CA; Marcovina SM; Gemin M; Seidah NG; Boffa MB; Koschinsky ML
PLoS One; 2017; 12(7):e0180869. PubMed ID: 28750079
[TBL] [Abstract][Full Text] [Related]
23. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.
Gordts PL; Nock R; Son NH; Ramms B; Lew I; Gonzales JC; Thacker BE; Basu D; Lee RG; Mullick AE; Graham MJ; Goldberg IJ; Crooke RM; Witztum JL; Esko JD
J Clin Invest; 2016 Aug; 126(8):2855-66. PubMed ID: 27400128
[TBL] [Abstract][Full Text] [Related]
24. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
[TBL] [Abstract][Full Text] [Related]
25. Hepatic inactivation of murine
Tang VT; McCormick J; Xu B; Wang Y; Fang H; Wang X; Siemieniak D; Khoriaty R; Emmer BT; Chen XW; Ginsburg D
Elife; 2022 Oct; 11():. PubMed ID: 36193893
[TBL] [Abstract][Full Text] [Related]
26. Differential cholesterol uptake in liver cells: A role for PCSK9.
Luquero A; Vilahur G; Casani L; Badimon L; Borrell-Pages M
FASEB J; 2022 May; 36(5):e22291. PubMed ID: 35344222
[TBL] [Abstract][Full Text] [Related]
27. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
[TBL] [Abstract][Full Text] [Related]
28. Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps.
Baragetti A; Grejtakova D; Casula M; Olmastroni E; Jotti GS; Norata GD; Catapano AL; Bellosta S
Pharmacol Res; 2018 Apr; 130():1-11. PubMed ID: 29428206
[TBL] [Abstract][Full Text] [Related]
29. The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA.
Susan-Resiga D; Girard E; Kiss RS; Essalmani R; Hamelin J; Asselin MC; Awan Z; Butkinaree C; Fleury A; Soldera A; Dory YL; Baass A; Seidah NG
J Biol Chem; 2017 Feb; 292(5):1573-1590. PubMed ID: 27998977
[TBL] [Abstract][Full Text] [Related]
30. Somatic Editing of Ldlr With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research.
Jarrett KE; Lee C; De Giorgi M; Hurley A; Gillard BK; Doerfler AM; Li A; Pownall HJ; Bao G; Lagor WR
Arterioscler Thromb Vasc Biol; 2018 Sep; 38(9):1997-2006. PubMed ID: 30026278
[TBL] [Abstract][Full Text] [Related]
31. Alginate oligosaccharide enhances LDL uptake via regulation of LDLR and PCSK9 expression.
Yang JH; Bang MA; Jang CH; Jo GH; Jung SK; Ki SH
J Nutr Biochem; 2015 Nov; 26(11):1393-400. PubMed ID: 26320675
[TBL] [Abstract][Full Text] [Related]
32. Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).
Ben Djoudi Ouadda A; Gauthier MS; Susan-Resiga D; Girard E; Essalmani R; Black M; Marcinkiewicz J; Forget D; Hamelin J; Evagelidis A; Ly K; Day R; Galarneau L; Corbin F; Coulombe B; Çaku A; Tagliabracci VS; Seidah NG
Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):1996-2013. PubMed ID: 31553664
[TBL] [Abstract][Full Text] [Related]
33. CCC- and WASH-mediated endosomal sorting of LDLR is required for normal clearance of circulating LDL.
Bartuzi P; Billadeau DD; Favier R; Rong S; Dekker D; Fedoseienko A; Fieten H; Wijers M; Levels JH; Huijkman N; Kloosterhuis N; van der Molen H; Brufau G; Groen AK; Elliott AM; Kuivenhoven JA; Plecko B; Grangl G; McGaughran J; Horton JD; Burstein E; Hofker MH; van de Sluis B
Nat Commun; 2016 Mar; 7():10961. PubMed ID: 26965651
[TBL] [Abstract][Full Text] [Related]
34. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.
Lambert G; Jarnoux AL; Pineau T; Pape O; Chetiveaux M; Laboisse C; Krempf M; Costet P
Endocrinology; 2006 Oct; 147(10):4985-95. PubMed ID: 16794006
[TBL] [Abstract][Full Text] [Related]
35. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
36. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
Canuel M; Sun X; Asselin MC; Paramithiotis E; Prat A; Seidah NG
PLoS One; 2013; 8(5):e64145. PubMed ID: 23675525
[TBL] [Abstract][Full Text] [Related]
37. Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects.
Taskinen MR; Björnson E; Andersson L; Kahri J; Porthan K; Matikainen N; Söderlund S; Pietiläinen K; Hakkarainen A; Lundbom N; Nilsson R; Ståhlman M; Adiels M; Parini P; Packard C; Borén J
J Clin Lipidol; 2020; 14(1):77-87. PubMed ID: 31917184
[TBL] [Abstract][Full Text] [Related]
38. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
39. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
[TBL] [Abstract][Full Text] [Related]
40. Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection.
Caron J; Pène V; Tolosa L; Villaret M; Luce E; Fourrier A; Heslan JM; Saheb S; Bruckert E; Gómez-Lechón MJ; Nguyen TH; Rosenberg AR; Weber A; Dubart-Kupperschmitt A
Stem Cell Res Ther; 2019 Jul; 10(1):221. PubMed ID: 31358055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
